Zur Rose Group nominates Rongrong Hu for upcoming election to its Board of Directors

– SWITZERLAND, Frauenfeld –  Zur Rose Group (SWX: ROS) today announced the nomination of Rongrong Hu for election to its Board of Directors at the next AGM to be held on 28 April 2022, bringing the Board to at least 30 percent female members.

“We are delighted to have been able to persuade Rongrong Hu to stand for our board. As a proven expert in e-commerce and technology with broad business experience, she is an ideal addition,” commented Board Chairman, Prof. Stefan Feuerstein. 

Following the previously announced departures of Dr. Thomas Schneider and Prof. Dr. Volker Amelung at the next AGM, the Board will shrink from seven to six members.

About Rongrong Hu

Rongrong Hu, a 41-year-old Chinese national, has been living in Switzerland since 2016 and is an investor focusing on the technology sector. Previously she worked for eBay as Senior Director of Innovation, M&A & Business Development EMEA, and Chief Strategy Officer Greater China. Before that, she worked for McKinsey & Company, CITIC Capital, and was the founder of various businesses. Rongrong Hu graduated with a dual Bachelor’s Degree in Telecommunication Engineering and International Economics & Trading from Shanghai Jiaotong University and holds an MBA from Harvard Business School.

About Zur Rose Group

The Swiss Zur Rose Group is Europe’s largest e-commerce pharmacy and one of the leading medical wholesalers in Switzerland. It also operates the leading marketplace in southern Europe for consumer health, beauty, and personal care products commonly sold in pharmacies. The company is internationally present with strong brands, including Germany’s best-known pharmacy brand, DocMorris, and employs more than 2,200 people at sites in Switzerland, Germany, the Netherlands, Spain, and France. Now serving more than 12 million active customers in core European markets, Zur Rose generated external revenue of CHF 1,752 million in 2020.

With its business model, the Zur Rose Group offers high-quality, safe, and cost-effective pharmaceutical care. It also excels in the continuous development of digital healthcare services and as a platform technology provider. In addition, Zur Rose is actively driving forward its positioning as a comprehensive healthcare service provider, with a focus on building up its European healthcare ecosystem networking qualified providers of products, services, and digital solutions. Zur Rose’s contribution will be to bring these offerings to customers and patients, pursuing its vision of creating a world where people can manage their health in one click.

The shares of Zur Rose Group AG are listed on the SIX Swiss Exchange (securities number 4261528, ISIN CH0042615283, ticker ROSE). For further information, please visit zurrosegroup.com.

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.